It’s a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain.
The post The MFN Executive Order: A Global Reset for U.S. Pharma appeared first on MedCity News.
